Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$2.44 +0.4%	$2.74	$2.06 ▼ $24.93	$7.08M	-0.32	662,776 shs	73,086 shs
BCLI Brainstorm Cell Therapeutics	$0.76 +4.1%	$0.87	$0.52 ▼ $4.85	$8.39M	0.12	593,926 shs	56,550 shs
CAPS Capstone Therapeutics	$1.22	$1.47	$0.96 ▼ $16.18	$6.81M	-0.8	1.22 million shs	210,154 shs
VBIV VBI Vaccines		$0.23	$0.06 ▼ $1.35	$1.87M	2.18	3.66 million shs	29.90 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	-1.22%	+3.40%	-6.54%	-39.70%	-88.61%
BCLI Brainstorm Cell Therapeutics	+2.82%	+15.69%	-1.35%	-36.51%	-84.79%
CAPS Capstone Therapeutics	-0.81%	+20.79%	-31.46%	-32.97%	+121,999,900.00%
VBIV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	+262.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALZN Alzamend Neuro	2.8771 of 5 stars	3.5	2.0	0.0	0.0	2.3	3.3	0.6
BCLI Brainstorm Cell Therapeutics	1.7045 of 5 stars	0.0	5.0	0.0	4.7	0.6	0.8	0.6
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	3.00	Buy	$45.00	1,744.26% Upside
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
CAPS Capstone Therapeutics	0.00	N/A	N/A	N/A
VBIV VBI Vaccines	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VBIV, CAPS, BCLI, and ALZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	ALZN Alzamend Neuro	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$180.00 ➝ $45.00
7/23/2025	BCLI Brainstorm Cell Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$4.95 per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
CAPS Capstone Therapeutics	$44.88M	0.15	N/A	N/A	$4.70 per share	0.26
VBIV VBI Vaccines	$9.41M	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$4.51M	N/A	0.00	N/A	N/A	N/A	-181.34%	-116.84%	9/10/2025 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.10	N/A	N/A	N/A	N/A	N/A	-519.50%	11/13/2025 (Estimated)
CAPS Capstone Therapeutics	-$2.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	-$92.84M	N/A	0.00	N/A	N/A	-881.79%	-525.42%	-45.87%	N/A

Latest VBIV, CAPS, BCLI, and ALZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/10/2025	N/A	ALZN Alzamend Neuro	-$3.69	N/A	N/A	N/A	N/A	N/A
8/15/2025	Q2 2025	CAPS Capstone Therapeutics	N/A	-$0.13	N/A	-$0.13	N/A	$12.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPS Capstone Therapeutics	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	6.58	6.58
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
CAPS Capstone Therapeutics	0.22	0.97	0.41
VBIV VBI Vaccines	N/A	0.34	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
BCLI Brainstorm Cell Therapeutics	14.33%
CAPS Capstone Therapeutics	2.55%
VBIV VBI Vaccines	12.26%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	30.21%
BCLI Brainstorm Cell Therapeutics	11.15%
CAPS Capstone Therapeutics	42.80%
VBIV VBI Vaccines	10.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	2.90 million	2.02 million	No Data
BCLI Brainstorm Cell Therapeutics	40	11.04 million	8.74 million	Optionable
CAPS Capstone Therapeutics	38	5.58 million	3.19 million	N/A
VBIV VBI Vaccines	22	28.68 million	25.71 million	Optionable

VBIV, CAPS, BCLI, and ALZN Headlines

Recent News About These Companies

Brii Biosciences buying VBI Vaccine’s hepatitis B therapy

January 24, 2025 | ncbiotech.orgN

VBI Vaccines Restructures and Acquired by K2 VBI Trust

January 3, 2025 | tipranks.com

VBI recalls PreHevbrio and winds down operations

November 20, 2024 | thepharmaletter.comT

Hepatitis B Vaccine PreHevbrio Recalled Due to Company Bankruptcy

November 19, 2024 | empr.comE

VBI Vaccines recalls hepatitis B shot as it winds down operations

November 18, 2024 | fiercepharma.comF

VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations

November 15, 2024 | businesswire.com

VBI Vaccines Inc. (VBIV): Unpacking the 80% Stock Surge During Restructuring

August 6, 2024 | bovnews.comB

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

August 6, 2024 | investorplace.com

VBI Vaccines to be delisted from Nasdaq following restructuring

August 4, 2024 | investing.com

VBI Vaccines Provides an Update on its Restructuring Proceedings

August 3, 2024 | finance.yahoo.com

VBI Vaccines secures court protection for restructuring

August 1, 2024 | investing.com

VBI craters as investors react to Hep B vaccine data

July 31, 2024 | pharmaphorum.comP

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

July 30, 2024 | stockhouse.com

VBI Vaccines Announces Results of Annual General Meeting

June 25, 2024 | businesswire.com

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

May 29, 2024 | businesswire.com

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

May 22, 2024 | businesswire.com

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

May 15, 2024 | investorplace.com

VBI Vaccines Reports First Quarter 2024 Financial Results

May 15, 2024 | businesswire.com

VBI Vaccines expands partnership with Canadian government on a vaccine platform

May 13, 2024 | plant.caP

VBI Vaccines Reports Full Year 2023 Financial Results

April 16, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIV, CAPS, BCLI, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$2.44 +0.01 (+0.41%)

Closing price 03:59 PM Eastern

Extended Trading

$2.44 0.00 (0.00%)

As of 04:17 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Brainstorm Cell Therapeutics NASDAQ:BCLI

$0.76 +0.03 (+4.11%)

As of 03:57 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Capstone Therapeutics NASDAQ:CAPS

$1.22 0.00 (0.00%)

As of 04:00 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time